Journal
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 40, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.nano.2021.102494
Keywords
P-glycoprotein; Nanomaterials; P-gp inhibition; Acquired P-gp overexpression; Nanomedicine; Cancer
Ask authors/readers for more resources
Multidrug resistance (MDR) is a growing concern in cancer chemotherapy, with P-glycoprotein (P-gp) overexpression being one of the major reasons. Nanotechnology-based drug delivery systems offer opportunities to overcome MDR by bypassing or inhibiting the P-gp efflux pump.
Multidrug resistance (MDR) in cancer chemotherapy is a growing concern for medical practitioners. P-glycoprotein (P-gp) overexpression is one of the major reasons for multidrug resistance in cancer chemotherapy. The P-gp overexpression in cancer cells depends on several factors like adenosine triphosphate (ATP) hydrolysis, hypoxia-inducible factor 1 alpha (HIF-1 alpha), and drug physicochemical properties such as lipophilicity, molecular weight, and molecular size. Further multiple exposures of anticancer drugs to the P-gp efflux protein cause acquired P-gp overexpression. Unique structural and functional characteristics of nanotechnology-based drug delivery systems provide opportunities to circumvent P-gp mediated MDR. The primary mechanism behind the nanocarrier systems in P-gp inhibition includes: bypassing or inhibiting the P-gp efflux pump to combat MDR. In this review, we discuss the role of P-gp in MDR and highlight the recent progress in different nanocarriers to overcome P-gp mediated MDR in terms of their limitations and potentials. (C) 2021 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available